20th Nov 2018 12:45
LONDON (Alliance News) - SkinBioTherapeutics PLC said Tuesday it started the final phase of its in-human study of its SkinBiotix technology.
The life science business, focused on skin health, said that the final phase of the study seeks to ensure that the original SkinBiotix technology "retains the same beneficial property to improve skin barrier health when in a cream formulation".
The firm expects the first results from its volunteers to be available for analysis at the end of December, with the full read out on all 120 volunteers expected during the first quarter of 2019.
Chief Executive Officer Cath O'Neill said: "The board is pleased with the progress made so far during 2018 in achieving a number of important product development milestones which have taken the SkinBiotix technology closer to commercialisation in a cosmetic skin product.
"SkinBiotix can now be manufactured to a commercially relevant scale, freeze dried for extended shelf life and has been formulated into a skin cream which has shown no significant safety or irritancy effects in a human study. These milestones, both individually and collectively, have reduced development risk, changed the risk reward ratio and are intended to increase interest from potential global partners."
SkinBio shares were trading up 2.9% at 16.20 pence each.
Related Shares:
Skinbiotherap.